FDA puts up a red light for Passage Bio’s first gene therapy program

The FDA has some questions about the program, and regulators dropped a hold on Passage’s IND, delaying the start to Phase I until the R&D group at Passage $PASG can work out a response that can satisfy regulators’ safety concerns regarding “the biocompatibility of the proposed ICM delivery device.”